Sai Parenteral’s IPO Price: ₹372 to ₹392 per share
IPO Dates: 24th March – 27th March 2026
Company Overview
Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
Business Segments
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
Product Portfolio
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Market Presence
Sai Parenteral’s serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Manufacturing Facilities
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Workforce
Sai Parenteral’s serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Competitive Strength
- Diversified generic formulations player with an established track record
- Strategically located and accredited manufacturing facilities
- Strong focus on CDMO business
- Well-established distribution network in India and overseas
- Track record of value-accretive acquisitions
- Experienced promoters and senior management with extensive domain knowledge
Bidding Starts In
Sai Parenteral’s IPO Specifics:
| IPO Date | 24 to 27 Mar, 2026 |
| Listing Date | Thu, Apr 2, 2026 |
| Face Value | ₹5 per share |
| Price Band | ₹372 to ₹392 |
| Lot Size | 38 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,04,28,288 shares (agg. up to ₹409 Cr) |
| Fresh Issue | 72,70,408 shares (agg. up to ₹285 Cr) |
| Offer for Sale | 31,57,880 shares of ₹5 (agg. up to ₹124 Cr) |
| Share Holding Pre Issue | 3,69,08,823 shares |
| Share Holding Post Issue | 4,41,79,231 shares |
Sai Parenteral’s IPO Timetable (Important Dates)
| Event | Date |
|---|---|
| IPO Open | Tue, Mar 24, 2026 |
| IPO Close | Fri, Mar 27, 2026 |
| Allotment | Mon, Mar 30, 2026 |
| Refund | Wed, Apr 1, 2026 |
| Credit of Shares | Wed, Apr 1, 2026 |
| Listing | Thu, Apr 2, 2026 |
Sai Parenteral’s IPO Lot Size
Bidders have the opportunity to bid for a minimum of 38 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,896 |
| Retail (Max) | 13 | 494 | ₹1,93,648 |
| S-HNI (Min) | 14 | 532 | ₹2,08,544 |
| S-HNI (Max) | 67 | 2,546 | ₹9,98,032 |
| B-HNI (Min) | 68 | 2,584 | ₹10,12,928 |
Sai Parenteral’s IPO Reservation
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Net Offer |
Sai Parenteral’s IPO Financial Information
| Particulars (₹ Cr) | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| Net Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves & Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
Key Performance Indicator – Sai Parenteral’s IPO
| KPI | Value |
|---|---|
| ROE | 16.82% |
| ROCE | 28.92% |
| RoNW | 15.09% |
| PAT Margin | 8.88% |
| EBITDA Margin | 24.18% |
| Price to Book Value | 10.89 |
| EPS (₹) | 5.43 |
| P/E (x) | 72.19 |
| Promoter Holding | 61.23% |
| Market Cap | ₹1,731.83 Cr. |
Prospectus Links:
Prospectus: Official documents that provide detailed information about the IPO and the company.
Kaashika is a social media strategist and financial content creator at Lakshmishree. She specialises in simplifying complex IPO and stock market concepts into clear, easy-to-understand content. Having created over 500+ pieces of financial content across reels, blogs, website posts and digital creatives, Kaashika helps audiences connect with the world of finance in a more accessible and engaging way.
